bluebird bio (Columbia) and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy (12/14/2010)

bluebird bio is a Columbia spinoff developing innovative gene therapies for severe genetic disorders. The company was founded by Dr. Arthur Bank, who was Head of the Division of Hematology at Columbia-Presbyterian Medical Center.

From the company’s press release:
Cambridge, Mass. and Evry, France, December 14, 2010 – bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research collaboration focused on process development and scale up efforts for the manufacturing of lentiviral vectors. This agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners. It will also strengthen bluebird bio’s manufacturing platform to enable robust, commercial-scale manufacturing and broaden the company’s capabilities in Europe. Specific terms of the agreement were not disclosed. read full press release


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: